Chad Robins is the Chief Executive Officer and Chairman at Adaptive Biotechnologies Corp, a company focused on revolutionizing the diagnosis and treatment of diseases such as cancer and autoimmune disorders through the use of immune system profiling. With a robust background in biotechnology and life sciences, Robins has been instrumental in steering the company towards its mission of harnessing the power of the adaptive immune system to improve human health. Before co-founding Adaptive Biotechnologies in 2009, he served as the President and Chief Executive Officer of Rosetta Inpharmatics, a leading genomics company that was acquired by Merck & Co., Inc. in 2001. Under Robins' leadership, Adaptive Biotechnologies has achieved significant milestones, including the development of innovative diagnostic tools such as clonoSEQ, which is used for the detection and monitoring of minimal residual disease (MRD) in blood cancers. His strategic vision has also led to successful collaborations with major pharmaceutical companies like Genentech and Amgen, further expanding the reach and impact of Adaptive's technologies. Robins' commitment to advancing the field of immunosequencing has earned him recognition as a thought leader in the biotech industry, and he frequently speaks at conferences and events to share insights on the future of personalized medicine. As CEO and Chairman, Chad Robins plays a pivotal role in shaping the company's direction and fostering a culture of innovation and scientific excellence. He oversees the company's operations, strategic planning, and partnerships, ensuring that Adaptive Biotechnologies remains at the forefront of immune-driven medicine. His leadership has been crucial in navigating the complexities of the biotech landscape, from securing funding and managing clinical trials to driving the commercialization of new products. Robins' dedication to improving patient outcomes through cutting-edge technology continues to drive Adaptive Biotechnologies forward, positioning the company as a key player in the rapidly evolving field of immunotherapy.